当前位置： SCI文献检索 > OncoImmunology期刊下所有文献 > Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.

Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.

Abstract：

:Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequence of endoplasmatic reticulum (ER)-stress induced by proteasome inhibition. Here we show that bortezomib sensitizes MM cells to NK cell killing via two distinct mechanisms: a) upregulation of the TRAIL death receptor DR5 on the surface of MM cells and b) ER-stress induced reduction of cell surface HLA-E. The latter mechanism is completely novel and was found to be exclusively controlled by the inhibitory receptor NKG2A, with NKG2A single-positive (NKG2ASP) NK cells developing a selective augmentation in tumor killing as a consequence of bortezomib-induced loss of HLA-E on the non-apoptotic MM cells. In contrast, the expression of classical HLA class I molecules remained unchanged following bortezomib exposure, diminishing the augmentation of MM killing by NK cells expressing KIR. Further, we found that feeder cell-based ex vivo expansion of NK cells increased both NK cell TRAIL surface expression and the percentage of NKG2ASP NK cells compared to unexpanded controls, substantially augmenting their capacity to kill bortezomib-treated MM cells. Based on these findings, we hypothesize that infusion of ex vivo expanded NK cells following treatment with bortezomib could eradicate MM cells that would normally evade killing through proteasome inhibition alone, potentially improving long-term survival among MM patients.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

doi

10.1080/2162402X.2018.1534664

subject

Has Abstract

pub_date

2018-11-02 00:00:00

pages

e1534664

issue

2

eissn

2162-4011

issn

2162-402X

pii

1534664

journal_volume

8

pub_type

杂志文章

相关文献

OncoImmunology文献大全
  • Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.

    abstract：:Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyz...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2019.1638210

    authors： Kreutzman A,Yadav B,Brummendorf TH,Gjertsen BT,Hee Lee M,Janssen J,Kasanen T,Koskenvesa P,Lotfi K,Markevärn B,Olsson-Strömberg U,Stentoft J,Stenke L,Söderlund S,Udby L,Richter J,Hjorth-Hansen H,Mustjoki S

    更新日期：2019-07-13 00:00:00

  • β3-adrenoreceptor and tumor microenvironment: a new hub.

    abstract：:The achievement of malignant traits in several cancers is associated with tumor microenvironment reactivity. New evidence show that the stress hormone noradrenaline enhances melanoma microenvironment reactivity, mainly acting through β3-adrenoreceptors (β2-ARs), favoring recruitment of cancer-associated fibroblasts, M...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2015.1026532

    authors： Chiarugi P,Filippi L

    更新日期：2015-04-02 00:00:00

  • A PI3K p110α-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice.

    abstract：:Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. Isoform-selective PI3K inhibitors elicit anti-tumor immune responses that are distinct from those induced by inhibitors of ...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2017.1421890

    authors： Choi JH,Kim KH,Roh KH,Jung H,Lee A,Lee JY,Song JY,Park SJ,Kim I,Lee WS,Seo SK,Choi IW,Fu YX,Yea SS,Park S

    更新日期：2018-01-16 00:00:00

  • A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage.

    abstract：:Whether fibroblasts regulate immune response is a crucial issue in the modulation of inflammatory responses. Herein, we demonstrate that foreskin fibroblasts (FFs) potently inhibit CD3+ T cell proliferation through a mechanism involving early apoptosis of activated T cells. Using blocking antibodies, we demonstrate th...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2015.1091146

    authors： Dezutter-Dambuyant C,Durand I,Alberti L,Bendriss-Vermare N,Valladeau-Guilemond J,Duc A,Magron A,Morel AP,Sisirak V,Rodriguez C,Cox D,Olive D,Caux C

    更新日期：2015-10-29 00:00:00

  • The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions.

    abstract：:The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictiv...

    journal_title：Oncoimmunology

    pub_type： 杂志文章,评审

    doi：10.1080/2162402X.2020.1796003

    authors： Lanzi A,Sinicrope FA,Benson AB,Galon J

    更新日期：2020-07-20 00:00:00

  • Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond.

    abstract：:Chimeric antigen receptors (CARs) possess fixed specificity for a single antigen and require empirical testing in T cells. To address this, we have developed a novel, adaptable immune receptor strategy that allows for the rapid generation and testing of T cells of nearly infinite antigen specificity. ...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.19730

    authors： Urbanska K,Powell DJ

    更新日期：2012-08-01 00:00:00

  • Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.

    abstract：:We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP-870,893 and the CT...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2018.1468956

    authors： Bajor DL,Mick R,Riese MJ,Huang AC,Sullivan B,Richman LP,Torigian DA,George SM,Stelekati E,Chen F,Melenhorst JJ,Lacey SF,Xu X,Wherry EJ,Gangadhar TC,Amaravadi RK,Schuchter LM,Vonderheide RH

    更新日期：2018-08-20 00:00:00

  • Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).

    abstract：:TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4-1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed, overexpression of A2...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2017.1368605

    authors： Azpilikueta A,Bolaños E,Lang V,Labiano S,Aznar MA,Etxeberria I,Teijeira A,Rodriguez-Ruiz ME,Perez-Gracia JL,Jure-Kunkel M,Zapata JM,Rodriguez MS,Melero I

    更新日期：2017-09-21 00:00:00

  • Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.

    abstract：:Tumor infiltrating lymphocytes (TIL) in Epstein-Barr virus (EBV)-associated/microsatellite-unstable (MSI) gastric carcinomas (GC) constitute immune-active principal cellular components of tumor microenvironment and contribute to better prognosis. With the remarkable success of cancer immunotherapies, there is an urgen...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2017.1356150

    authors： Park C,Cho J,Lee J,Kang SY,An JY,Choi MG,Lee JH,Sohn TS,Bae JM,Kim S,Kim ST,Park SH,Park JO,Kang WK,Sohn I,Jung SH,Kang MS,Kim KM

    更新日期：2017-08-10 00:00:00

  • Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling.

    abstract：:Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however, little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Here, we show that the ecrg4 null glioma-initiating cell (GIC) line, which was generated from neural stem cells of ecrg4 knockout (K...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2016.1242547

    authors： Moriguchi T,Kaneumi S,Takeda S,Enomoto K,Mishra SK,Miki T,Koshimizu U,Kitamura H,Kondo T

    更新日期：2016-10-14 00:00:00

  • EBV infection determines the immune hallmarks of plasmablastic lymphoma.

    abstract：:Despite recent therapeutic progress, plasmablastic lymphoma (PBL), a distinct entity of high grade B cell lymphoma, is still an aggressive lymphoma with adverse prognosis. PBL commonly occurs in patients with HIV infection and PBL cells frequently express Epstein Barr virus (EBV) genome with type I latency. Occasional...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2018.1486950

    authors： Gravelle P,Péricart S,Tosolini M,Fabiani B,Coppo P,Amara N,Traverse-Gléhen A,Van Acker N,Brousset P,Fournie JJ,Laurent C

    更新日期：2018-07-30 00:00:00

  • eIF2α phosphorylation: A hallmark of immunogenic cell death.

    abstract：:Immunogenic cell death (ICD) induced by anticancer chemotherapeutics is usually preceded by premortem stress affecting the endoplasmic reticulum (ER). This ER stress does not reflect a canonical unfolded protein response (UPR) but rather manifests solely at the level of the phosphorylation of eIF2α. eIF2α phosphorylat...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2018.1431089

    authors： Bezu L,Sauvat A,Humeau J,Leduc M,Kepp O,Kroemer G

    更新日期：2018-02-14 00:00:00

  • NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.

    abstract：:NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results h...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.21059

    authors： Lai JP,Rosenberg AZ,Miettinen MM,Lee CC

    更新日期：2012-11-01 00:00:00

  • Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

    abstract：:Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT ce...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2017.1339855

    authors： Ghinnagow R,De Meester J,Cruz LJ,Aspord C,Corgnac S,Macho-Fernandez E,Soulard D,Fontaine J,Chaperot L,Charles J,Soncin F,Mami-Chouaib F,Plumas J,Faveeuw C,Trottein F

    更新日期：2017-08-18 00:00:00

  • Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome.

    abstract：:Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited curative therapeutic options. Immunotherapy for EOC is promising, but clinical efficacy remains restricted to a small percentage of patients. Several lines of evidence suggest that the low response rate might be improved by com...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2020.1760705

    authors： Brunekreeft KL,Paijens ST,Wouters MCA,Komdeur FL,Eggink FA,Lubbers JM,Workel HH,Van Der Slikke EC,Pröpper NEJ,Leffers N,Adam J,Pijper H,Plat A,Kol A,Nijman HW,De Bruyn M

    更新日期：2020-05-13 00:00:00

  • Tregs activated by bispecific antibodies: Killers or suppressors?

    abstract：:In recent years, bispecific antibodies (bsAb) have emerged as promising tools for a target-specific redirection of T cells in order to eliminate malignant cells. However, CD3-engaging constructs might also activate T regulatory cells (Tregs) present in the tumor microenvironment. Whether this has detrimental or benefi...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/2162402X.2014.994441

    authors： Koristka S,Cartellieri M,Arndt C,Feldmann A,Seliger B,Ehninger G,Bachmann MP

    更新日期：2015-01-23 00:00:00

  • The next step toward GMP-grade production of engineered immune cells.

    abstract：:Removing less potent T cell subsets as well as poorly- or non-engineered cells can optimize effectiveness of engineered T cell therapy against cancer. We have recently described a novel, GMP-ready method for the purification of engineered immune cells that might further boost the clinical success of cancer immunothera...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2015.1076608

    authors： Kierkels GJ,Straetemans T,de Witte MA,Kuball J

    更新日期：2015-08-27 00:00:00

  • Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.

    abstract：:Acute infection is known to induce strong anti-tumor immune responses, but clinical translation has been hindered by the lack of an effective strategy to safely and consistently provoke a therapeutic response. These limitations are overcome with a novel treatment approach involving repeated subcutaneous delivery of a ...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2017.1398875

    authors： Bazett M,Costa AM,Bosiljcic M,Anderson RM,Alexander MP,Wong SWY,Dhanji S,Chen JM,Pankovich J,Lam S,Sutcliffe S,Gunn H,Kalyan S,Mullins DW

    更新日期：2017-11-27 00:00:00

  • Immune effectors responsible for the elimination of hyperploid cancer cells.

    abstract：:The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is con...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2018.1463947

    authors： Aranda F,Chaba K,Bloy N,Garcia P,Bordenave C,Martins I,Stoll G,Tesniere A,Kroemer G,Senovilla L

    更新日期：2018-05-21 00:00:00

  • The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.

    abstract：:Tumor-associated macrophages (TAM) are immunosuppressive cells that can massively accumulate in the tumor microenvironment. In patients with ovarian cancer, their density is correlated with poor prognosis. Targeting mediators that control the generation or the differentiation of immunoregulatory macrophages represents...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2016.1178025

    authors： d'Almeida SM,Kauffenstein G,Roy C,Basset L,Papargyris L,Henrion D,Catros V,Ifrah N,Descamps P,Croue A,Jeannin P,Grégoire M,Delneste Y,Tabiasco J

    更新日期：2016-04-28 00:00:00

  • Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.

    abstract：:A substantial obstacle to the success of adoptive T cell-based cancer immunotherapy is the sub-optimal affinity of T-cell receptors (TCRs) for most tumor antigens. Genetically engineered TCRs that have enhanced affinity for specific tumor peptide-MHC complexes may overcome this barrier. However, this enhancement risks...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2019.1682381

    authors： Sanderson JP,Crowley DJ,Wiedermann GE,Quinn LL,Crossland KL,Tunbridge HM,Cornforth TV,Barnes CS,Ahmed T,Howe K,Saini M,Abbott RJ,Anderson VE,Tavano B,Maroto M,Gerry AB

    更新日期：2019-11-24 00:00:00

  • Immune cells in pancreatic cancer: Joining the dark side.

    abstract：:Pancreatic tumors are rich in immune cell infiltrates that include CD4+ T-cell subsets encompassing both regulatory T cells and TH17 cells. Rather than protecting the organism by exerting an anticancer effect, these T-cell subsets promote tumor formation. Thus, re-activation of antitumor immunity should be investigate...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.29125

    authors： Zhang Y,McAllister F,Pasca di Magliano M

    更新日期：2014-06-05 00:00:00

  • Glycan-mediated modification of the immune response.

    abstract：:Aberrantly glycosylated tumor antigens represent promising targets for the development of anti-cancer vaccines, yet how glycans influence immune responses is poorly understood. Recent studies have demonstrated that GalNAc-glycosylation enhances antigen uptake by dendritic cells as well as CD4+ T-cell and humoral respo...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.23659

    authors： Madsen CB,Pedersen AE,Wandall HH

    更新日期：2013-04-01 00:00:00

  • Alerting the immune system via stromal cells is central to the prevention of tumor growth.

    abstract：:Anticancer immunotherapies are highly desired. Conversely, unwanted inflammatory or immune responses contribute to oncogenesis, tumor progression, and cancer-related death. For non-immunogenic therapies to inhibit tumor growth, they must promote, not prevent, the activation of anticancer immune responses. Here, the ce...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.27091

    authors： Issazadeh-Navikas S

    更新日期：2013-12-01 00:00:00

  • Zfra induction of memory anticancer response via a novel immune cell.

    abstract：:When naive mice receive short Zfra peptides via tail vein injections, they develop lifetime resistance to growth of many cancer xenografts, due to activation of a novel spleen memory Hyal-2+ CD3- CD19- Z lymphocyte. In vitro education of spleen cells with Zfra activates Z cell for conferring memory anticancer response...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2016.1213935

    authors： Su WP,Wang WJ,Sze CI,Chang NS

    更新日期：2016-07-28 00:00:00

  • The role of NF-kB in modulating antitumor immunity.

    abstract：:Recent breakthroughs in therapeutic modulation of immune cells have led to novel exciting treatments for cancers. Moreover, the cytokine milieu in the tumor microenvironment is important for appropriate immune surveillance. Here, we demonstrate that NF-κB activity in myeloid cells is essential for cytokine-mediated an...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2015.1005522

    authors： Richmond A,Yang J

    更新日期：2015-10-20 00:00:00

  • Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.

    abstract：:Prolonged lymphopenia correlating with decreased survival commonly occurs among glioma patients undergoing radiation therapy (RT) and temozolomide (TMZ) treatment. To better understand the pathophysiology of this phenomenon, we prospectively monitored serum cytokine levels and lymphocyte subsets in 15 high-grade gliom...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/onci.27357

    authors： Ellsworth S,Balmanoukian A,Kos F,Nirschl CJ,Nirschl TR,Grossman SA,Luznik L,Drake CG

    更新日期：2014-01-01 00:00:00

  • Toward a rational design of combination therapy in cancer.

    abstract：:By merging computational systems modeling and experimental approaches, we have uncovered treatments reprogramming pro-angiogenic monocytes present in breast tumor into immunologically potent cells capable of mediating an anti-tumor immune response. The unraveled pathways and ligands which underlie monocyte pro-angioge...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2015.1046674

    authors： Doucey MA,Xenarios I

    更新日期：2015-07-07 00:00:00

  • Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.

    abstract：:Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant subgroups to improve our understanding of pathogenetic mechanisms and patient stratification. Concurrently, the role of immune cells i...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.1080/2162402X.2019.1655360

    authors： Kaffes I,Szulzewsky F,Chen Z,Herting CJ,Gabanic B,Velázquez Vega JE,Shelton J,Switchenko JM,Ross JL,McSwain LF,Huse JT,Westermark B,Nelander S,Forsberg-Nilsson K,Uhrbom L,Maturi NP,Cimino PJ,Holland EC,Kettenmann H,

    更新日期：2019-08-22 00:00:00

  • Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.

    abstract：:Human papillomavirus (HPV) infection is one of the most important etiologic causes of oropharyngeal head and neck squamous cell carcinoma (HNSCC). Patients with HPV-positive HNSCC were reported to have a better clinical outcome than patients with HPV-negative cancers. However, little is known about the possible causes...

    journal_title：Oncoimmunology

    pub_type： 杂志文章

    doi：10.4161/21624011.2014.965570

    authors： Partlová S,Bouček J,Kloudová K,Lukešová E,Zábrodský M,Grega M,Fučíková J,Truxová I,Tachezy R,Špíšek R,Fialová A

    更新日期：2015-01-30 00:00:00